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Abstract
Intermediate filament (IF) proteins are known to be regulated by a number of post-translational 
modifications (PTMs). Phosphorylation is the best studied IF PTM, whereas ubiquitination, 
sumoylation, acetylation, glycosylation, ADP-ribosylation, farnesylation and transamidation are 
less understood in functional terms but are known to regulate specific IFs under various contexts. 
The number and diversity of IF PTMs is certain to grow along with rapid advances in proteomic 
technologies. Therefore, the need for a greater understanding of the implications of PTMs to the 
structure, organization, and function of the IF cytoskeleton has become more apparent with the 
increased availability of data from global profiling studies of normal and diseased specimens. This 
chapter will provide information on established methods for the isolation and monitoring of IF 
PTMs along with the key reagents that are necessary to carry out these experiments.
1. Introduction
1.1. Post-translational modifications of intermediate filament proteins
IF proteins are important for the maintenance of cellular function in the basal state, and are 
particularly important under stress and in disease states (Omary 2009, Davidson and 
Lammerding 2014, Gruenbaum and Aebi 2014, Homberg and Magin 2014, Toivola, Boor et 
al. 2015). IFs are major structural components of the cell cytoskeleton, but through their 
dynamic behavior and under varying cellular conditions, they have also been demonstrated 
to impact virtually every aspect of cellular function, including gene transcription, signaling 
pathways and cellular survival (Herrmann, Strelkov et al. 2009, Toivola, Strnad et al. 2010, 
Chung, Rotty et al. 2013). The assembly and disassembly dynamics of IF proteins, as well as 
their associations with other cellular components are regulated by various post-translational 
modifications (PTMs), summarized in Table 1, and a myriad of enzymes that carry out 
specific PTM on/off reactions (Omary, Ku et al. 2006, Hyder, Pallari et al. 2008, Snider and 
Omary 2014).
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1.2 Available tools and major limitations for the study of IF protein PTMs
The extent of functional understanding regarding the role of each PTM on IF protein 
function is highly dependent on the availability of tools to study the particular PTM of 
interest. For example, phosphorylation (Roux and Thibault 2013) and ubiquitination 
(Sylvestersen, Young et al. 2013) can be analyzed using mass spectrometry with relative 
ease, whereas sumoylation (Gareau and Lima 2010), which has relatively low stoichiometry 
and is not easily analyzed by mass spectrometric means, is more difficult to probe. 
Therefore, the systems-level PTM data currently available is skewed to highlight those 
PTMs that can be readily tracked using proteomic platforms (Choudhary and Mann 2010, 
Hennrich and Gavin 2015). The combination of global proteomic data with PTM databases 
that catalog experimentally-determined and site-specific modifications, or that use 
computational approaches to predict and quantify PTMs (Table 2), has resulted in a wealth 
of information on modified residues on IF proteins. However, most of these modifications 
await functional assignment. For most IF protein PTMs, the use of molecular approaches 
(e.g. site-directed mutagenesis of modification sites), biochemical tools (pan- or site-specific 
PTM antibodies), chemical probes (inhibitors or activators of PTM enzymes) and transgenic 
mouse models, in combination with enrichment of the IF protein fraction from cells and 
tissues, has yielded useful insight into some of the functional roles of PTMs, although much 
more remains to be learned. The relative insolubility of IF proteins (particularly epidermal 
keratins) in nondenaturing detergent-containing buffers can be an impediment to the study of 
PTMs, although these limitations can be surmounted, as it was shown for the case of the 
type I keratin K17 (Pan, Kane et al. 2011).
1.3. Cross-talk between PTMs on IF proteins
PTMs participate in complex cross-talk mechanisms to regulate IF function. The balance of 
various modified forms of IF proteins is dictated by cellular conditions, such as mitosis, cell 
migration, stress and apoptosis. The key to resolving the information encoded by IF PTMs is 
to determine which PTM signatures are prevalent under a given condition and how altering 
the stoichiometry of IF PTMs alters IF function, distribution, interactions and, ultimately, 
cellular fate.
Using the database PhosphoSitePlus (Hornbeck, Zhang et al. 2015) we conducted a search 
for PTMs on human keratin 8 (K8) that have been reported by at least one low-throughput 
study, or those that appear in at least five high-throughput studies/records (Table 3). In this 
case, low-throughput refers to data generated via amino acid sequencing, site-directed 
mutagenesis, or the use of specific antibodies, whereas high throughput refers to studies 
using unbiased discovery-mode mass spectrometry. This example analysis revealed that 16% 
(76/483) of residues on K8 are modified by either phosphorylation, acetylation, 
ubiquitination, sumoylation, or methylation. The majority of the PTM sites on K8 (47/76) 
are modified by phosphorylation (p-Ser > p-Tyr > p-Thr). It can also be appreciated that 
most of the acetylation sites are also targets for ubiquitination, and one residue (Lys-285) 
appears to be capable of undergoing sumoylation, acetylation or ubiquitination. These 
observations suggest that, depending on the cellular conditions, the various PTMs may 
directly compete for a given site. In addition to direct competition, there is experimental 
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evidence for functional cross-talk between the different PTMs, such as between 
phosphorylation and ubiquitination, sumoylation, and acetylation (Snider and Omary 2014).
1.4. Chemical and pharmacological approaches to study context-specific IF protein PTMs
Regulation of IF proteins by PTMs occurs under specific cellular conditions, which can be 
modeled using chemical and pharmacological agents. An abbreviated list of representative 
reagents is shown in Table 4. Hyperphosphorylation of IF proteins can be induced by 
treatment with phosphatase inhibitors, such as okadaic acid or microcystin-LR. 
Phosphorylation, in turn, can promote IF protein sumoylation, so these two modifications 
are generally observed together, particularly under conditions of oxidative stress and 
apoptosis (Snider, Weerasinghe et al. 2011). The latter can be modeled in cells using 
hydrogen peroxide and anisomycin, respectively, among numerous other reagents that can 
induce similar responses. Increased acetylation of K8 in epithelial cells is dose-responsive to 
glucose levels in vitro and in vivo, and can be induced more robustly if the cells undergo 
transient glucose starvation prior to re-stimulation (Snider, Leonard et al. 2013). Increased 
O-glycosylation of K18 in vitro and in vivo is observed in response to PUGNAc (Ku, 
Toivola et al. 2010), an inhibitor of the enzyme that removes O-linked N-acetylglucosamine 
(O-GlcNAc) groups (O-GlcNAcase). Since many IF proteins (Rogel, Jaitovich et al. 2010) 
are turned over by ubiquitination and proteasomal degradation, treatment with the 
proteasome inhibitor MG-132 promotes the accumulation of poly-ubiquitinated IF proteins. 
The sections that follow describe the general methods for isolation of IF proteins from cells 
and tissues, followed by a summary of specific tools and approaches to study more common 
PTMs on IF proteins.
2. Extraction of IF proteins from tissues and cells for biochemical analysis 
of IF PTMs
2.1. Materials and reagents for isolation of IF proteins
Source of IF protein:
• Human or animal tissue
• Primary cells (e.g. freshly isolated hepatocytes)
• Cultured cells expressing endogenous IF proteins
• Cultured cells over-expressing IF protein(s) of interest
Antibodies and immunoprecipitation beads:
• Anti-IF protein antibodies
• Anti-PTM antibodies (pan- or site-specific)
• IgG isotype control
• Dynabeads magnetic beads (or similar)
Buffers:
• TXB: Triton-X Buffer
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○ 1% Triton-X 100
○ 5mM EDTA
○ Bring up volume in PBS, pH 7.4
• TXB+PPI: Triton-X Buffer with Protease and Phosphatase Inhibitors
Immediately before use, add protease and phosphatase inhibitors (follow 
manufacturer instructions) to the desired volume of TXB to be used in the 
experiment.
• HSB: High Salt Buffer:
○ 10mM Tris-HCl, pH 7.6
○ 140mM NaCl
○ 1.5M KCl
○ 5mM EDTA
○ 0.5% Triton-X100
○ Bring up volume in double distilled (dd) H2O
• HSB+PPI: High Salt Buffer with Protease and Phosphatase Inhibitors
Immediately before use, add protease and phosphatase inhibitors (follow 
manufacturer instructions) to the desired volume of TXB to be used in the 
experiment.
• PBS/EDTA:
5mM EDTA in 1X PBS, pH 7.4. The EDTA is included to protect from calcium-
activated protease-related degradation (Chou, Riopel et al. 1993)
• 2X SDS Sample Buffer
• Coomassie-based stain compatible with mass spectrometry applications (e.g. Gel 
Code Blue)
2.2 High Salt Extraction (HSE) of IF Proteins
1a. (If using tissue): Cut 10-25mg of freshly-isolated or snap-frozen tissue from 
liquid nitrogen storage and place directly into 1mL of ice-cold TXB+PPI on ice. 
Dounce (50 strokes) to a homogeneous suspension using a Potter-Elvehjem 
PTFE pestle and glass tube homogenizer (7mL working volume size).
1b. (If using cells): Collect cells by scraping (if adherent) and centrifugation at 500g 
for 5 min. For cells grown to 80-95% confluency on a 100mm dish (~60cm2 
growth surface area) use 2mL of 1X PBS to collect the cells. For a cell pellet 
with approximate volume of 50-100μL add 1-2mL of ice cold TXB+PPI and 
solubilize the pellet by pipetting. Leave tubes sitting on ice for 5-10 min.
2. Centrifuge tissue or cell lysate (14,000rpm) for 10 min at 4°C.
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3. Collect the supernatant fraction. This is the TXB-soluble fraction, which can be 
used to immunoprecipitate (i.p.) the detergent-soluble pool of IF proteins 
(Section 2.3.).
Note: under basal conditions ~5% of the cellular K8/K18 pool can be extracted 
from the human colonic cell line HT-29 in a detergent-free buffer, while a total 
of ~20% can be extracted using the non-ionic detergent Nonidet P-40 which is 
similar to the TXB buffer (Chou, Riopel et al. 1993, Omary, Ku et al. 1998). The 
K8/K18 soluble fraction increases during mitosis (Chou, Riopel et al. 1993) but 
is much smaller for epidermal keratins but likely higher for vimentin and other 
type III IF proteins (Lowthert, Ku et al. 1995, Omary, Ku et al. 1998). However, 
only 0.18-0.39% of vimentin in the rat cell line RVF-SMC was reported to be 
soluble (Soellner, Quinlan et al. 1985), although this may represent an 
underestimate based on how vimentin was isolated using single-stranded DNA-
cellulose columns from [35S]-methionine pulse labeled cells. In terms of keratin 
content in simple-type epithelial cells and tissues, K8/K18 make up 5% of total 
cellular protein in HT-29 cells (Chou, Riopel et al. 1993) and 0.2-0.5% of total 
tissue protein in mouse pancreas, liver and small intestine (Zhong, Zhou et al. 
2004); while human epidermal keratins make up 25-35% of total cellular 
proteins in human keratinocytes (Sun and Green 1978) and 17-27% of newborn 
mouse keratinocytes (Feng, Zhang et al. 2013).
4. Resuspend the cell pellet in 1mL of HSB+PPI by douncing (100 strokes) and 
leave on the shaker in the cold room for 1hr.
Note: the 1hr shaking step is important for obtaining clean high salt extracts. In 
general, the HSE purity ranks: cell line over-expressed IFs > cell line 
endogenous IFs > tissue IFs. Therefore, this step is the most critical when 
working with tissues.
5. Centrifuge the samples at 14,000 rpm for 20min at 4°C. Discard the supernatant, 
which contains histones and other nuclear proteins that are not solubilized in 
TXB (step 1).
6. Homogenize the pellet in 1mL of ice-cold PBS/EDTA buffer and centrifuge at 
14,000rpm for 10 min at 4°C to obtain the IF protein-rich high salt extract 
(HSE).
7. Dissolve the HSE pellets in 200-400μL of 2X reducing or non-reducing SDS 
sample buffer that has been pre-heated to 95°C. Break up the pellet initially by 
pipetting/vortexing, then heat the samples for 5 min at 95°C. Vortex and pipet as 
needed to ensure the pellet is dissolved.
Note: the temperature and the volume of the buffer are critical for ensuring that 
the entire pellet goes into solution. Dissolving the entire pellet may require 5-15 
min of vortexing and pipetting per sample, depending on the pellet size.
8. Proceed with downstream analysis:
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• Analyze the HSEs by SDS-PAGE followed by Coomassie stain to check 
the enrichment of IF proteins (an abbreviated protocol and example gel 
are shown in Figure 1).
Note: The pellets used in the gels that are shown in Figure 1 were 
completely solubilized prior to loading on the gels. We have obtained 
HSEs of vimentin and GFAP with similar purity by following this 
extraction protocol (e.g., vimentin can be readily seen as noted in Figure 
3B).
• Analyze the HSE samples by Western blot using PTM antibodies (pan- or 
site-specific)
○ Useful antibodies for specific PTMs are noted in each sub-section.
• If sufficient material is present on Coomassie-stained gel, excise the IF 
bands for proteomic analysis by mass spectrometry.
○ Note: special precautions must be taken in order to avoid 
contamination: gels must be handled with clean gloves and incubated in 
clean containers, which should only be washed using ddH2O (no soap); 
note that keratins are typically considered common “contaminants” of 
mass spectrometry experiments.
• Alternatively, proteomic analysis may be performed on the total HSE (in-
solution digest)
○ Note: A consultation with a proteomics expert is necessary to discuss 
the various needs and options for a given experiment prior to initiating 
a study.
2.3. Immunoprecipitation of detergent-soluble IF proteins
1. Aliquot 50μL of Dynabeads (e.g. Dynabeads protein-G) into an Eppendorf tube, 
place on the magnet and aspirate storage solution.
2. Resuspend the beads in the antibody solution (1-10μg of antibody in 200μL of PBS
+0.02% Tween-20) and incubate on rotator (end-over-end) at room temperature for 
20 min.
3. Aspirate antibody solution and wash beads once with 200μL of PBS+0.02% 
Tween-20. Add 600μL of the cell or tissue lysate (save a small fraction of the 
original lysate to check the protein levels in the pre-i.p. input, as described in step 
8).
○ Note: Lysis buffers containing different detergents (e.g. NP-40 or Empigen-
BB) may be used. Empigen-containing lysis buffers solubilize a larger pool of IF 
protein (Lowthert, Ku et al. 1995), although they may disrupt certain interactions 
with IF binding partners.
4. Incubate for 3hr with rotation in a cold room.
5. Place samples on magnet and save the post-i.p. fraction for quality control in step 8.
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6. Wash the beads five times with 200μL of PBS+0.02% Tween-20. For the last wash 
step, collect the beads in 100μL of PBS (without Tween-20) and transfer to a new 
tube.
7. Remove the PBS and add 60-100μL of hot non-reducing sample buffer, heat the 
samples to 95°C for 5min and separate the i.p. fraction from the beads on the 
magnet and collect it into a new tube.
○ Note: It is necessary to use non-reducing buffer so that the antibody IgG heavy 
chain (which, when reduced, migrates at ~50kDa) does not obscure the IF protein 
bands on an SDS-PAGE gel. Alternatively the antibody can be crosslinked to the 
beads to avoid co-elution (follow manufacturer guidelines for the specific 
crosslinking procedure).
8. As a quality check, analyze equivalent amounts of the pre-i.p. lysate (from step 3), 
post-i.p. lysate (from step 5), and the i.p. fraction (from step 7) on an SDS-PAGE 
gel and probe for the presence of the IF protein of interest. If significant amounts of 
protein remain in the post-i.p. fraction, vary the ratio of antibody to lysate in order 
to achieve immunodepletion.
○ Note: We generally use 3μg of anti-human keratin 18 (L2A1 or DC10 clones; 
see Table 1 in (Ku, Toivola et al. 2004) for list of antibodies to simple epithelial 
keratins) antibody per 600μL of HT-29 (human colon cancer cell line) lysate. We 
optimize this step based on the type and starting number of cells, rather than total 
protein concentration, because IF protein amounts will be highly variable 
depending on the starting material.
9. Proceed with downstream analysis:
• Perform Coomassie stain to check the enrichment of IF proteins in the HSE 
fraction; excise the IF band of interest for proteomic analysis by mass spec.
○ An abbreviated protocol and example gel are shown in Figure 2.
• Perform the immunoblot using antibodies to the IF protein/PTM of interest 
(pan- or site-specific).
• Perform proteomic analysis of the total i.p. fraction (in-solution digest).
○ Note: antibody bead cross-linking is ideal for an in-solution digest in 
order to avoid signal interference from the immunoglobulins.
3. Methods for monitoring specific PTMs on IF proteins
The subsections below describe the functional significance and the available tools and 
methods to study several IF protein PTMs: phosphorylation, sumoylation, acetylation, 
glycosylation, and transamidation. For specific methods for the analysis of other PTMs, such 
as farnesylation (Hannoush and Sun 2010), ubiquitination (Lill and Wertz 2014), and ADP-
ribosylation (Moyle and Muir 2010) we direct the readers to general protocols and previous 
applications of these modifications in the context of IF proteins.
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3.1 Analysis of IF protein phosphorylation
Phosphorylation is the best characterized PTM of IF proteins (Omary, Ku et al. 2006, Snider 
and Omary 2014). Most of the known phosphorylation sites on IF proteins are Ser and Thr 
residues found in the globular head and tail domains, although proteomic studies have also 
revealed numerous phosphorylation sites in the rod domain that only recently began to 
undergo functional characterization (Snider, Park et al. 2013). One major function of IF 
phosphorylation is to facilitate the reorganization, and the assembly-disassembly dynamics 
of IF proteins (Izawa and Inagaki 2006, Sihag, Inagaki et al. 2007, Snider and Omary 2014). 
With the exception of neurofilaments, basal phosphorylation of IF proteins is minimal but 
becomes significantly upregulated during stress, mitosis, disease states, and in the presence 
of mutations that have structural effects on IF proteins. Multiple approaches can be used to 
study IF phosphorylation, including chemical inhibitors and activators, phospho-specific 
antibodies, mass spectrometry, and transgenic mice. A list of phospho site-specific 
antibodies targeting different human IF proteins available through major suppliers is shown 
in Table 5. Additionally, pan-pSer/Thr and pan-pTyr antibody are widely available and may 
be used for biochemical detection of IF protein phosphorylation sites on IF protein-enriched 
samples in combination with proper experimental controls. As an example, the pan-
phospho-Tyr antibody pY100 (Cell Signaling) recognizes human K8 phosphorylation at 
Tyr-267 (Snider, Park et al. 2013).
3.1.1. Specific materials needed to study IF protein phosphorylation
• Kinase or phosphatase inhibitors
○ Commercially available with varying degree of target selectivity
○ Note: To study epithelial keratin phosphorylation we frequently use okadaic 
acid and microcystin-LR (Gehringer 2004) for in vitro and in vivo studies, 
respectively (Toivola, Zhou et al. 2002).
• Expression plasmids or siRNA against various kinases or phosphatases
○ Useful for examining PTM regulation mechanisms
• Phospho-site specific or pan-phospho antibodies
○ Table 3: most antibodies can be used for immunoblotting and some antibodies 
are also suitable for immunohistochemistry
• HSE fraction or IF immunoprecipitates obtained by following Protocol 2.2 and 2.3
○ Samples are prepared after chemical or genetic manipulation to alter kinase or 
phosphatase activity or induce stress conditions
○ Note: phosphatase inhibitor treatment will increase the presence of IF proteins 
in the detergent-soluble pool, whereas some stress conditions (e.g. oxidative 
stress) will lead to IF protein aggregation. Therefore, both the insoluble (HSE) 
and soluble (i.p.) fractions should always be examined
Figure 3 provides two different examples for monitoring keratin 8 phosphorylation. 
Phosphorylation of K8 Ser-74 (panel A) serves as a phosphate “sponge” during stress (Ku 
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and Omary 2006). Phosphorylation of K8 Tyr-267 (panel B) is important for filament 
organization, since the phospho-deficient Y267F mutation results in short and mostly 
perinuclear filaments and the phospho-mimetic Y267D mutation leads to K8/K18 
aggregation (Snider, Park et al. 2013).
3.2. Analysis of IF protein sumoylation
Cytoplasmic IFs and nuclear lamins are targets for sumoylation, which entails the covalent 
addition of Small Ubiquitin-like Modifier (SUMO) proteins to Lysine residues on specific 
targets (Gareau and Lima 2010). Monosumoylation of lamin-A under basal conditions 
appears to be important for the proper organization of the nuclear lamina (Zhang and Sarge 
2008). On the other hand, epithelial K8, K18 and K19 are modified by polymeric 
SUMO-2/3 chains primarily under conditions where the filament structures are altered, such 
as during stress or in the context of disease-associated mutations, and in these cases 
sumoylation likely functions (at least in part) to modulate the solubility of keratin IFs 
(Snider, Weerasinghe et al. 2011). Sumoylation of mammalian IF proteins can be studied in 
an in vitro reconstituted system or in cells and tissues. However, given that the fraction of 
sumoylated proteins is very small, experimental conditions that alter the stoichiometry of 
SUMO conjugation/deconjugation reactions are required in most cases to detect this 
modification on IF proteins. Sumoylation generally occurs within the classic consensus 
linear motif ΨKX[D/E] (Ψ and X denote a hydrophobic residue and any residue, 
respectively), although there are exceptions (Gareau and Lima 2010). Sequence-based 
predictions should be performed as a first step using the freely available programs, such as 
SUMOplot (Abgent), GPS-SUMO, SUMOsp, and SUMOFI to aid with the experimental 
analysis.
3.2.1. Specific materials needed to study IF protein sumoylation
• In vitro sumoylation components:
○ Purified IF protein
○ Recombinant E1 and E2 SUMO ligases
○ SUMO proteins (SUMO-1, −2, or −3)
○ ATP
○ Note: for beginning investigations these components can be purchased as a 
SUMOylation kit (Enzo Life Sciences) and the reactions carried out following 
published procedures or manufacturer specifications. As controls, reactions 
lacking ATP or substrate should be performed routinely.
• SUMO antibodies
○ Available from multiple commercial sources. We have used a rabbit polyclonal 
antibody to SUMO-2/3 (Abcam; ab3742).
○ Can be used for immunoblotting, immunocytochemistry or 
immunoprecipitation
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○ Note: immunoprecipitation using anti-SUMO antibodies may prove 
challenging in the context of hyper-sumoylation due to masking of antibody 
epitopes.
• HSE fraction or IF immunoprecipitates obtained by Following Protocol 2.2 and 2.3
○ N-ethylmalimide (20mM) should be added to the lysis buffer (e.g. TXB+PPI) 
to inhibit de-sumoylation during the sample processing.
○ Mono-sumoylation will result in a ~15kDa increase in the molecular mass of 
the protein, whereas hypersumoylation appears as a smear of high molecular 
mass complexes, some of which might be trapped at the top of the gel. Therefore, 
the entire membrane should be probed during immunoblotting.
Figure 4 provides examples for monitoring IF protein sumoylation biochemically and by 
immunofluorescence analysis. Note that the sumoylation sites on K8, K18 and K19 are 
located in the rod domains (Snider, Weerasinghe et al. 2011). Therefore, co-expression of 
K8/K18 or K8/K19 pairs results in significantly diminished sumoylation relative to 
expression of each protein individually, likely due to limited access of the relevant enzyme 
in the context of heterodimer formation that involves the rod domains of the keratin pairs.
3.3. Analysis of IF protein lysine acetylation
Acetylation of lysine residues is a common modification on numerous cellular proteins, and 
is best known for histones and enzymes involved in energy metabolism (Choudhary, Weinert 
et al. 2014). IF proteins represent a separate category of targets for this modification, with a 
large number of acetylation sites determined by mass spectrometry proteomic studies. 
However, experimental validation has only been reported on human K8, where a single 
residue (Lys-207) was found to be acetylated in response to glucose stimulation, inhibition 
or knockdown of the NAD-dependent deacetylase SIRT2, and in the presence of the NAD 
synthesis inhibitor FK-866 (Snider, Leonard et al. 2013). The acetylation-deficient mutant of 
K8 (K207R) forms filaments but lacks the ability to assemble into a dense perinuclear 
network that is seen with WT K8, and shows diminished phosphorylation at Ser-74 (Snider, 
Leonard et al. 2013). Therefore, lysine acetylation on K8 may couple the metabolic 
conditions to K8 phosphorylation and filament reorganization. Since there are no known 
consensus motifs for lysine acetylation, mass spectrometry can be used to identify acetylated 
sites on IFs and numerous acetylated residues on IF proteins have already been catalogued in 
databases like PhosphoSitePlus.
3.3.1 Specific materials needed to study IF protein lysine acetylation
• Acetyl-lysine antibodies
○ Note: There are a number of these available from commercial sources. 
However, the reactivity profiles of these antibodies vary significantly, as shown 
by immunoblot comparison of 3 antibodies using normal mouse liver lysates 
(Figure 5A). Therefore, multiple antibodies should be tested for their ability to 
recognize the IF protein of interest. We used a rabbit polyclonal anti-acetyl lysine 
antibody (Abcam; ab80178) to monitor human K8 acetylation.
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• Inhibitor of NAD synthesis (to test involvement of NAD-dependent sirtuins)
○ FK-866
• Inhibitors of Sirtuin deacetylase enzymes
○ SIRT1/2 inhibitor: Salermide
○ SIRT2 inhibitor: AGK-2
• pan-histone deacetylase (HDAC) inhibitor: trichostatin A
Currently the best available methods for detecting lysine acetylation on IF proteins are 
immunoprecipitation with a pan-acetyl lysine antibody followed by mass spectrometry 
analysis to identify the acetylated residues. Site directed mutagenesis to substitute candidate 
lysines to nonacetylatable arginines or acetylation-mimetic glutamines can narrow down the 
major sites, as shown for K8 (Figure 5B). Immunofluorescence staining analysis may also 
be useful in some cases. Note that the nuclear AcK staining (acetylated histones) is usually 
the major signal detected, although the presence/absence of cytoplasmic staining can also be 
examined in the context of acetylation site mutants (Figure 5C-D).
3.4. Analysis of IF protein O-linked glycosylation
Several IF proteins (K8, K13, K18, vimentin and NFs) are known to be regulated by O-
linked glycosylation (Snider and Omary 2014), a modification that involves the covalent 
attachment of β-D-N-acetylglucosamine (O-GlcNAc) to Ser/Thr residues (Hardiville and 
Hart 2014). Functionally, O-linked glycosylation of K18 (Chou, Smith et al. 1992, Ku and 
Omary 1995) protects epithelial cells from injury by interfering with the phosphorylation 
and activation of stress kinases (Ku, Toivola et al. 2010). In general, O-linked glycosylation 
is important in the maintenance of metabolic homeostasis and therefore, its broader 
functional significance to the regulation of IF protein function may fully come to light by 
examining various conditions of altered metabolism or metabolic stress.
3.4.1 Specific materials needed to study IF protein O-linked glycosylation
• Antibodies to O-Linked N-Acetylglucosamine
○ RL2, HGAC85 (Abcam, Pierce, Novus)
• Inhibitors of GlcNAc-β-N-acetylglucosaminidase
○ PUGNAc, Thiamet G (Cayman Chemical, Sigma, Tocris)
• Inducers of metabolic stress
○ Streptozotocin (Cayman Chemical, Sigma, Tocris)
• IF protein glycosylation-deficient mice (K18 Gly−/−)
○ mice that over-express glycosylation-deficient human K18 (Ser30, Ser31 and 
Ser49 converted to Ala)
• Reagents for in vitro O-glycosylation
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○ may be performed on IF immunoprecipitates or HSEs by incubation with 
radiolabeled UDP-(4, 5-3H)-galactose and recombinant galactosyltransferase 
(Ku, Toivola et al. 2004) to label terminal O-GlcNAc residues.
○ non-radioactive methods for in vitro labeling of O-GlcNac modification 
include “click” chemistry approaches, such as the commercially available Click-
iT O-GlcNAc Enzymatic Labeling System (Life Technologies).
3.5. Analysis of IF protein transamidation
Transamidation is a covalent PTM that involves formation of amide bonds between the ε- 
amino group of Lys and the γ- carboxyl group of Gln residues (Iismaa, Mearns et al. 2009). 
Epidermal and epithelial keratins are substrates of transglutaminase-2 (TG2), the calcium-
dependent enzyme that catalyzes these reactions (Strnad, Harada et al. 2007). 
Transglutamination of type II epidermal keratins is involved in the maintenance of skin 
barrier function, whereas in the liver transglutamination of K8/K18 occurs in pathologic 
settings to promote the formation of the K8/K18-containing aggregates called Mallory-Denk 
bodies (Strnad Gastro 2007). Although TG2-mediated cross-linking of keratins can be 
monitored in vitro, methods for in vivo detection of this modification and the specific 
residues involved are currently lacking. Strong consensus sequences for transglutamination 
have not been identified, however phage display studies (Sugimura, Hosono et al. 2006, 
Hitomi, Kitamura et al. 2009) have revealed preferred sequences around the reactive 
glutamines to be: Qx(P,Y)ØD(P) and pQx(PTS)l, where: x=any; Ø=hydrophobic; p=polar; 
and l=aliphatic residue.
3.5.1 Specific materials needed to study IF protein transamidation
• Plasmids encoding WT IF proteins or Gln→Asn and Lys→Arg substituted mutants.
• Purified peptides containing potential transglutamination sites
• Recombinant transglutaminase enzyme
• Antibody that recognizes the isopeptide bond (antibody 81D1C2, available from 
abcam and Santa Cruz). However, there may be an issue with specificity of such 
antibodies (Johnson and LeShoure 2004).
4 Conclusions
There are several hundred known PTMs across the proteome, and we are just beginning to 
understand the information that they encode in order to promote adaptable functions of 
proteins under specific physiological and pathophysiological conditions. IF proteins are 
known to be regulated by a number of PTMs, but with the improvement in detection 
methods we will be able to uncover more details about the known IF PTMs as well as 
identify novel IF-targeting PTMs. Generation of new site-specific antibodies will be 
necessary in order to study PTM dynamics in physiologically-relevant systems. For some 
modifications, such as sumoylation, pharmacologic inhibitors of the conjugating and 
deconjugating enzymes are needed to further advance our understanding of this important 
modification. PTMs that target conserved IF protein domains are likely to have important 
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roles on multiple IF protein types, and may provide insight into novel cellular functions of 
IFs and how they fit into the greater function of the cell cytoskeleton. From a disease 
perspective, various pathologic states (in humans and in animal models) display a mix of 
cellular stress responses where changes in IF protein PTMs may serve as disease markers, 
especially given the abundance of IFs. Finally, pharmacological strategies to alter PTM 
regulation of IF proteins through inhibiting the activity of various enzymes may also prove 
to be important from a human disease perspective. The field is wide open in terms the 
pursuit of functional aspects of IF PTMs, and it is hoped that the tools described herein will 
promote this line of investigation.
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Figure 1. 
Isolation of intermediate filament proteins using high salt extraction. Shown is an 
abbreviated version of the protocol outlined in section 2.2. In the panel on the right, BHK 
cells are transfected with human K8 and K18 (+) or vector alone (−) and the HSE is 
compared from these cells is shown in parallel with the HSE from normal human liver.
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Figure 2. 
Immunoprecipitation of intermediate filament proteins from detergent-soluble fractions. 
Shown is an abbreviated version of the protocol outlined in section 2.3. Representative 
Coomassie-stained gels of transfected cell- and liver tissue-extracted K8/K18 are shown on 
the right.
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Figure 3. 
Biochemical analysis of K8 serine and tyrosine phosphorylation. A, The phosphatase 
inhibitor okadaic acid was used to upregulate K8 Ser/Thr phosphorylation, as detected in 
total HepG2 cell lysates by a site-specific antibody (LJ4, which recognizes human K8 
pSer-74). Total K8 was detected with the TS1 (mouse anti-human K8) antibody. Note the 
slight retardation in migration, which is typical of hyper-phosphorylated proteins. B, The 
pan-phosphotyrosine antibody pY100 antibody (Cell Signaling) was used to demonstrate 
that human K8 is phosphorylated at Tyr-267. In this case, the HSE fractions of BHK-21 cells 
expressing wild type (WT) or the phosphorylation-deficient Y267F mutant of human K8 
were analyzed, and shown are the pY100 immunoblot and Coomassie stain as a loading 
control. WT K18 was co-transfected in each case in order to allow stabilization of the 
partner K18; otherwise there would be degradation of the individual keratin by the 
proteasome (Ku and Omary 2000). The Coomassie-stained band that migrates above K8 
(arrow) corresponds to vimentin which is the major IF protein expressed in the transfected 
cells.
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Figure 4. 
Biochemical and immunofluorescence analysis of keratin sumoylation. A, extensive poly-
sumoylation (observed as ubiquitin-like smears on a SUMO-2/3 immunoblot) is observed 
when K8, K18 and K19 are transfected individually (i.e. without their obligate type I/II 
partner). This is due to the fact that sumoylation sites on K8/K18/K19 are located in the rod 
domains and are inaccessible to the SUMO proteins and their associated enzymes under 
basal conditions (in the context of intact heteropolymers). Note that large amounts of protein 
are needed to detect a signal, which is consistent with the low stoichiometry of sumoyolation 
(as seen by the Coomassie-stained gel in the top part of the panel). B, colocalization between 
an IF protein (K8, green) and SUMO-2/3 (red) is shown in the presence of the phosphatase 
inhibitor okadaic acid (1 μm, 45min).
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Figure 5. 
Monitoring lysine acetylation on IF proteins using pan-acetyl-lysine (AcK) antibodies. A, 
Comparison of three different pan-AcK antibodies by immunoblot on total liver lysates from 
two control mouse livers. Note the different protein profiles detected by each antibody. B, 
Identification of Lys-207 as an acetylation site on human K8 after immunoprecipitation 
using an anti-AcK antibody (Abcam antibody from panel A) and immunoblotting with TS1 
antibody against K8 (panel reproduced with permission from Snider et al. J Cell Biol 2013). 
C, Detection of K8 acetylation using immunofluorescence analysis of WT K8 and the 
K207R K8 mutant. Note the absence of cytoplasmic signal in the acetylation-deficient 
mutant. Blue=DAPI, Green=K8, Red=pan-AcK (Abcam antibody from panel A). D, 
quantification of cytoplasmic AcK signal (n=4). P<0.0001, unpaired t-test.
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Table 1
Post-translational modifications of IF proteins
IF Protein Major PTMs
Lamins phosphorylation, farnesylation, ubiquitination, sumoylation
Keratins phosphorylation, O-linked glycosylation, ubiquitination, sumoylation, acetylation, transamidation
Vimentin phosphorylation, O-linked glycosylation, ubiquitination, sumoylation, ADP-ribosylation
Peripherin phosphorylation, ubiquitination*
α-internexin phosphorylation*
Neurofilament (-L, -M, -H) phosphorylation, O-linked glycosylation, ubiquitination,
GFAP phosphorylation
Nestin phosphorylation
Desmin phosphorylation, ubiquitination, ADP-ribosylation
Synemin phosphorylation*
Syncoilin phosphorylation*
Filensin (BFSP1)# phosphorylation*
Phakinin (BFSP2) phosphorylation*
*
the modification has only been detected in high-throughput studies
#
BFSP, beaded filament structural protein
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Table 3
Example of Phosphosite database search for PTMs on human K8
# of studies/records
Residue Type of modification
# of studies/records
Site Type of modification
LTP* HTP** LTP HTP
2 24 9
Phosphorylation (Serine)
0 85 25
Phosphorylation (Tyrosine)
1 5 13 0 8 143
0 44 21 1 117 204
0 25 22 1 440 267
5 114 24 0 106 282
0 33 27 0 49 286
0 19 31 0 6 419
1 48 34 0 19 427
0 102 35 0 49 437
0 11 36 0 6 11
Ubiquitination (Lysine)
1 27 37 0 6 96
0 23 39 0 9 101
1 74 43 0 10 108
0 21 44 0 9 117
25 12 74 0 7 122
0 23 104 0 10 130
0 5 142 0 6 264
0 19 253 0 5 285
0 12 258 0 8 304
0 9 274 0 22 325
0 8 280 0 7 347
1 6 291 0 5 352
0 5 315 0 59 393
0 10 330 0 11 472
0 8 410 2 1 11
Acetylation (Lysine)
1 2 417 1 32 101
20 27 432 0 7 108
0 7 436 0 6 122
0 8 442 1 4 207
0 8 445 0 5 285
0 9 456 1 2 393
0 17 457 2 5 472
0 20 475 3 38 483
0 11 478 1 0 285
Sumoylation (Lysine)
0 24 26 Phosphorylation (Threonine) 1 0 364
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# of studies/records
Residue Type of modification
# of studies/records
Site Type of modification
LTP* HTP** LTP HTP
0 31 305 0 5 23
Methylation (Arginine)1 1 431 0 7 32
0 7 455 0 9 47
PhosphoSitePlus (Hornbeck, Zhang et al. 2015) was used to conduct a search for PTMs on human keratin 8 (K8). The search was limited to 
modified residues that have been reported by at least one low-throughput study (LTP), or those that appear in at least five high-throughput studies/
records (HTP). LTP refers to data generated via amino acid sequencing, site-directed mutagenesis, of the use of specific antibodies; HTP refers to 
studies using unbiased discovery-mode mass spectrometry.
*
LTP, low throughput
**
HTP, high throughput
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Table 5
Phospho-site specific antibodies
IF protein phosphorylation sites Commercial source(s)
Keratin 8 pSer-24, pSer-74, pSer-432 Abcam
Keratin 18 pSer-34, pSer-53 Abcam
Keratin 17 pSer-44 Cell Signaling
Vimentin pSer-34, pTyr-38, pSer-39, pSer-51, pSer-55, pSer-56, pTyr-61, pSer-72, 
pSer-83
Abcam, Cell Signaling, Sigma, Thermo Scientific
Desmin pSer-60 Abcam, Sigma
GFAP pSer-8, pSer-38 Abcam, Sigma
NF-M pSer-615/620 Abcam
NF-H KpSP repeat (NAP4 clone) Thermo Scientific
Lamin-A/C pSer-22, pSer-392 Abcam, Cell Signaling, Sigma, Thermo Scientific
Lamin-B1 pSer-575 Abcam
This is a list of IF protein phospho-antibodies available from four major antibody vendors. Note that it is not an exhaustive list, as it does not 
include investigator-generated antibodies or antibodies from smaller suppliers. Researchers should also be aware that the nomenclature may differ 
depending on the antibody source. For example, K8 pSer-24 may be catalogued as K8 pSer-23 in cases where the initiator methionine is not 
included in the count.
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